Plain-English translation of NCT07316127 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing immunoadsorption, a procedure that filters harmful antibodies from your blood, for people with long COVID. Researchers have discovered that some long COVID patients have specific antibodies that may be driving their symptoms, and this study will test whether removing these antibodies can help you feel better.
Long COVID affects many people, and current treatments are limited. Scientists found evidence that harmful immune proteins called antibodies may be causing symptoms in some patients, so this treatment aims to remove those specific antibodies and improve quality of life.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will be randomly assigned to receive either the active blood-cleaning treatment or a sham procedure (placebo) that looks the same but doesn't remove antibodies. Either way, you'll come in for six sessions over two weeks, each lasting 2.5 hours, where blood is circulated through a machine and returned to your body. The study uses a double-blind design, meaning neither you nor the researchers will know which treatment you're receiving until the trial ends.
AI-generated summary from trial data ยท Jun 6, 2026 ยท Not medical advice
Netherlands
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrollment target
~70 participants
Started
January 2026
Primary completion
December 2027
Age range
18 Years โ 65 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Daphne Schouten, MD
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.